eXoZymes Inc. Common Stock EXOZ Business Segments
| TTM Q1 '25 | ||
|---|---|---|
| Cumulative Net Sales by Product | ||
| Licensed Product | $1.75M— | |
| Second Licensed Product | $3.5M— | |
| Payments To Acquire Licensed Product by Product | ||
| Licensed Product | $437.5K— | |
| Second Licensed Product | $612.5K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does eXoZymes Inc. Common Stock break its business down?
- eXoZymes Inc. Common Stock (EXOZ) reports cumulative net sales by product across 2 parts — Licensed Product and Second Licensed Product. Each is extracted from the segment footnotes and tracked over time.
- Where does eXoZymes Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in eXoZymes Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
